BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2021

View Archived Issues

Classifying variants of unknown significance

Read More

Amyris announces promising preclinical data for its novel COVID-19 RNA vaccine platform

Read More

Novel COVID-19 MATE program candidate effectively neutralizes multiple strains of SARS-CoV-2

Read More

Curocell receives IND clearance in Korea for its CD19 CAR-T therapy, CRC-01

Read More

FDA clears IND for phase III trial of OT-101 for myopia

Read More

Targeting PI3K-driven HER2 expression in colorectal cancer stem cells

Read More

Topline data from phase III BRIGHT study of pegunigalsidase alfa for Fabry Disease

Read More

Inovio initiates dosing in phase Ib study of INO-4500 vaccine against Lassa Fever in West Africa

Read More

Pentaglobin to be evaluated in immunomodulatory therapy arm of ACOVACT COVID-19 study

Read More

Researchers patent new PROTACs

Read More

BeiGene discloses new PROTACs for cancer

Read More

Jinan University synthesizes new EGFR inhibitors

Read More

Medshine Discovery synthesizes FGFR and VEGFR dual inhibitors

Read More

The Titan Leading Med Tech discovers new GLP-1 receptor agonists

Read More

Elicio receives IND clearance for phase I/II trial of ELI-002

Read More

New phase I study evaluates AbFero's SP-420 to treat transfusional iron overload

Read More

Akeso reports phase III interim data on penpulimab with chemotherapy for squamous NSCLC

Read More

Amicus Therapeutics presents preclinical data for Fabry disease therapeutic AT-GTX-701

Read More

Activation of CARD8 inflammasome triggers pyroptosis of HIV-1-infected cells

Read More

China NMPA accepts IND for JS-111

Read More

Calpain-2 inhibition as a promising approach for treating seizure-induced neuropathology

Read More

Australian researchers identify potential treatment for fatal brain cancer in children

Read More

NeuroRx reports interim data from phase IIb/III trial of aviptadil in COVID-19

Read More

FDA clears IND for pilot study of NT-17 in progressive multifocal leukoencephalopathy

Read More

Nanoform reports further data from phase I study of Nanoformed piroxicam

Read More

Opthea prepares to begin pivotal phase III trials of OPT-302 in wet AMD

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing